Non-invasive imaging systems and methods of use

A method of treating cardiovascular diseases, comprising:

• obtaining a drug for treating cardiovascular diseases based on:
• an acquired ultraweak photon emission image of a target area of a patient;
• wherein the target area comprises an area of interest and a portion surrounding the area of interest,
• wherein acquired the ultraweak photon emission image comprises:
• enhancing formation of reactive oxygen species and/or reactive nitrogen species in the target area,
• wherein enhancing formation of the reactive oxygen species and/or the reactive nitrogen species comprises applying low level light illumination to the target area from 1 second to 60 minutes, and
• imaging the target area,
• wherein imaging the target area comprises a total exposure time from 1 second to 60 minutes;
• a measured amount of ultraweak photon emission in area of interest in the acquired image of the target area;
• and
• a correlation of the measured amount of ultraweak photon emission in the area of interest of the target area to the cardiovascular diseases reducing drug,
• wherein the cardiovascular diseases reducing drug is selected from group consisting of anticoagulants, aldosterone inhibitors, antiplatelet agents and dual antiplatelet therapy, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers, angiotensin receptor-neprilysin inhibitors, beta blockers, calcium channel blockers, cholesterol-lowering medications, digoxin, digitalis preparations, diuretics, inotropic therapy, proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors, vasodilators, anti-inflammatory drugs, or any combination thereof;
• and
• administering the cardiovascular disease reducing drug to treat the cardiovascular diseases.

A method of treating neurological disorders, comprising:

• obtaining a neurological disorder reducing drug for treating neurological disorder based on:
• an acquired ultraweak photon emission image of a target area of a patient;
• wherein the target area comprises an area of interest and a portion surrounding the area of interest,
• wherein acquired the ultraweak photon emission image comprises:
• enhancing formation of reactive oxygen species and/or reactive nitrogen species in the target area,
• wherein enhancing formation of the reactive oxygen species and/or the reactive nitrogen species comprises applying low level light illumination to the target area from 1 second to 60 minutes, and
• imaging the target area,
• wherein imaging the target area comprises a total exposure time from 1 second to 60 minutes;
• a measured amount of ultraweak photon emission in area of interest in the acquired image of the target area;
• and
• a correlation of the measured amount of ultraweak photon emission in the area of interest of the target area to the neurological disorder reducing drug,
• wherein the neurological disorder reducing drug is selected from group consisting of analgesics, anesthetics, anorexiants, anticonvulsants, antipyretics, antiemetic/antivertigo agents, antiparkinson agents, anxiolytics, sedatives, and hypnotics, cholinergic agonists, cholinesterase inhibitors, CNS stimulants, drugs used in alcohol dependence, general anesthetics, melatonin, miscellaneous central nervous system agents, muscle relaxants, neuromuscular blockers, neuroprotective agents, parasympathomimetics, psychoactive drugs, sympathomimetics, nervous system drug stubs, VMAT2 inhibitors, or any combination thereof;
• and
• administering the neurological disorder reducing drug to treat the neurological disorder.

A method of treating arthritis and other rheumatic conditions, comprising:

• obtaining an arthritis and other rheumatic conditions reducing drug for treating arthritis and other rheumatic conditions based on:
• an acquired ultraweak photon emission image of a target area of a patient;
• wherein the target area comprises an area of interest and a portion surrounding the area of interest,
• wherein acquired the ultraweak photon emission image comprises:
• enhancing formation of reactive oxygen species and/or reactive nitrogen species in the target area,
• wherein enhancing formation of the reactive oxygen species and/or the reactive nitrogen species comprises applying low level light illumination to the target area from 1 second to 60 minutes, and
• imaging the target area,
• wherein imaging the target area comprises a total exposure time from 1 second to 60 minutes;
• a measured amount of ultraweak photon emission in area of interest in the acquired image of the target area;
• and
• a correlation of the measured amount of ultraweak photon emission in the area of interest of the target area to the arthritis and other rheumatic conditions reducing drug,
• wherein the arthritis and other rheumatic conditions reducing drug is selected from group consisting of nonsteroidal anti-inflammatory drugs, counterirritants, anti-inflammatory drugs, disease-modifying antirheumatic drugs, biologic response modifiers, steroidal drug including but not limited to corticosteroids, Janus Kinase (JAK) inhibitors, or any combination thereof;
• and
• administering the arthritis and other rheumatic conditions reducing drug to treat the arthritis and other rheumatic conditions.